Thus, targeting Hx and Hp levels, vascular endothelial TLR4 inhibition, and reducing elevated levels of sMD2 can result in promising strategies in SCD treatment and other hemolytic conditions. This evidence concerns the gene TLR4 and Schnyder corneal dystrophy.